Assessment of some immune regulatory cytokines in rheumatoid arthritis patients immune regulatory cytokines In rheumatoid arthritis
Article Sidebar
Main Article Content
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by complex immune dysregulation which involves both the innate and adaptive immune systems. The study designed to determine demographic parameters and immune regulatory biomarker profiles of RA patients. A Total of 200 Rheumatoid arthritis patient and 50 age-and sex-matched healthy controls were included in the study. Demographically, the majority of patients were middle-aged, particularly in the 41-50 and 51-60 age groups. Patients with RA were also more women than men. Most patients were presented with a peak phase of the disease at 1–5 years of disease duration. Immunologic examination indicated that the serum levels of ICAM-1, DAF (CD55) and CD19 in RA patients were significantly higher than those in controls (P < 0.05). In contrast, CCR7 was more abundant in the patients but without significance. In conclusion, the results of the current study showed a distinct immune regulatory imbalance in RA patients, and support the potential of ICAM-1, DAF, and CD19 as biomarkers associated with disease activity and immune dysregulation.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The Journal of Medical and Oral Biosciences uses a Creative Commons Attribution (CC Attribution-ShareAlike 4.0) and its license of (CC BY-SA 4.0). This license allows the authors to hold ownership of the copyright of their articles.
Attribution-Share Alike 4.0 International License (CC BY-SA 4.0). 
Under the CC BY-SA 4.0 the authors are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
No use, distribution or reproduction is permitted which does not comply with these terms.
https://creativecommons.org/licenses/by-sa/4.0/
References
1. 1. Weyand CM, Goronzy JJ. The Immunology of Rheumatoid Arthritis. Nat
Immunol. 2021;22(1):10-18. DOI: https://doi.org/10.1038/s41590-020-00816-x
2. Mangoni AA, Zinellu A. A systematic review and meta-analysis of circulating adhesion molecules in rheumatoid arthritis. Inflamm Res. 2024 Mar;73(3):305-327. doi: 10.1007/s00011-023-01837-6. Epub 2024 Jan 19. PMID: 38240792; PMCID: PMC10894129.
3. Bahabayi A, Xiong Z, Li Q, Wang G, Liu R, Zhang K, Zhang Z, Gao Y, Wang P, Liu C. CD55 characterizes regulatory T cells with reduced functionality and is downregulated in rheumatoid arthritis. Int Immunopharmacol. 2025 Jan 3;145:113822. doi: 10.1016/j.intimp.2024.113822. Epub 2024 Dec 10. PMID: 39657534.
4. Freeley M. CAR T Cell Therapy for Rheumatoid Arthritis. Clin Rev Allergy Immunol. 2025 Nov 19;68(1):100. doi: 10.1007/s12016-025-09113-7. PMID: 41258618; PMCID: PMC12630179.
5. Van Raemdonck, K., Umar, S., Palasiewicz, K., Volkov S, Volin M V, Arami S, & Shahrara, S. CCL21/CCR7 signaling in macrophages promotes joint inflammation and Th17-mediated osteoclast formation in rheumatoid arthritis. Cellular and molecular life sciences: CMLS, 2019;77(7):1387-1399. DOI: https://doi.org/10.1007/s00018-019-03235-w
6. Geier, C., Qudsi, H., Khairallah, E., Ben Gabr, J., Winchester, R., & Perl, A. Spectral cytometry of rheumatoid arthritis patients implicates myeloid dendritic cells and granular HLA-DR+ CD15+ CD16+ cells in pro-inflammatory antigen presentation. Frontiers in Immunology, 16, 1596609.2025;16:1596609. DOI: https://doi.org/10.3389/fimmu. 2025 .1596609
7. Smolen JS, Aletaha D, McInnes IB. Rheumatoid Arthritis. Lancet. 2016;388(10055):2023-2038. Doi: https://doi.org/10.1001/jama.2018.13103
8. McInnes IB, Schett G. Pathogenetic Insights From the Treatment of Rheumatoid Arthritis. Lancet. 2017;389(10086):2328-2337. DOI: http://dx.doi.org/10.1016/S0140-6736 (17) 31472-1
9. Goronzy JJ, Shao L, Weyand CM. Immune Aging and Rheumatoid Arthritis. Rheum Dis Clin North Am. 2010;36(2):297-310. DOI: https://doi.org/10.1016/j.rdc.2010.03.001
10. Tutturen AE, Fleckenstein B, de Souza GA. Assessing the citrullinome in rheumatoid arthritis synovial fluid with and without enrichment of citrullinated peptides. J Proteome Res. 2014 Jun 6;13(6):2867-73. doi: 10.1021/pr500030x. Epub 2014 Apr 28. PMID: 24724574.
11. Zhang L, Zhang Y, Pan J. Immunopathogenic Mechanisms of Rheumatoid Arthritis and the Use of Anti-Inflammatory Drugs. Intractable Rare Dis Res. 2021;10(3):154-164. DOI: https://doi.org/10.5582/irdr.2021.01022
12. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis. 2002 Sep;61(9):804-9. doi: 10.1136/ard.61.9.804. PMID: 12176805; PMCID: PMC1754213.
13. Anand D, Kumar U, Kanjilal M, Kaur S, Das N. Leucocyte complement receptor 1 (CR1/CD35) transcript and its correlation with the clinical disease activity in rheumatoid arthritis patients. Clin Exp Immunol. 2014 Jun;176(3):327-35. doi: 10.1111/cei.12274. PMID: 24433281; PMCID: PMC4008976.
14. Jones J, Laffafian I, Cooper AM, Williams BD, Morgan BP. Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br J Rheumatol. 1994 Aug;33(8):707-12. doi: 10.1093/rheumatology/33.8.707. PMID: 8055195.
15. Chen L, Xu J, Sun B, Hong X, Liu D, Li H. The vital role of CD19+CD24hiCD38hi regulatory B cells in rheumatoid arthritis: correlations with disease activity and treatment response. Adv Rheumatol. 2025 Sep 26;65(1):43. doi: 10.1186/s42358-025-00474-3. PMID: 41013794.
16. Alenazy MF, Saheb Sharif-Askari F, Omair MA, El-Wetidy MS, Omair MA, Mitwalli H, Al-Muhsen S, Al-Masri A, Hamid Q, Halwani R. Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance. Sci Rep. 2021 Mar 11;11(1):5629. doi: 10.1038/s41598-021-83615-0. Erratum in: Sci Rep. 2021 Apr 13;11(1):8462. doi: 10.1038/s41598-021-87874-9. PMID: 33707483; PMCID: PMC7952390.
17. Wang Z, Xia Q, Su W, Zhang M, Gu Y, Xu J, Chen W, Jiang T. The commonness in immune infiltration of rheumatoid arthritis and atherosclerosis: Screening for central targets via microarray data analysis. Front Immunol. 2022 Oct 13;13:1013531. doi: 10.3389/fimmu.2022.1013531. PMID: 36311761; PMCID: PMC9606677.
18. Zhao F, Hu Z, Li G, Liu M, Huang Q, Ai K, Cai X. Angiogenesis in rheumatoid Arthritis: Pathological characterization, pathogenic mechanisms, and nano-targeted therapeutic strategies. Bioact Mater. 2025 May 2;50:603-639. doi: 10.1016/j.bioactmat.2025.04.026. PMID: 40453697; PMCID: PMC12124647.
19. Brühl H, Mack M, Niedermeier M, Lochbaum D, Schölmerich J, & Straub RH. Functional Expression of the Chemokine Receptor CCR7 on Fibroblast-Like Synoviocytes. Rheumatology (Oxford). 2008;47:1771-1774. DOI: https://doi.org/ 10.1093/rheumatology/ken383
20. Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nature Reviews Rheumatology. 2021;17(1):17-33.DOI: https://www.nature.com/articles/s41584-020-00541-7
21. Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 2015 Dec;14(12):857-77. doi: 10.1038/nrd4657. Epub 2015 Oct 23. PMID: 26493766; PMCID: PMC7098197.
22. Levesque MC. Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clinical and Experimental Immunology. 2009;157(2):198-208.DOI: https://doi.org/10.1111/j.1365-2249.2009.03979.x
23. Blüml S, McKeever K, Ettinger R, Smolen J, Herbst R. B-cell targeted therapeutics in clinical development. Arthritis Research & Therapy. 2013;15(1):S4. DOI: http://arthritis-research.com/content/15/S1/S4
24. Moschovakis GL, Bubke A, Friedrichsen M, Ristenpart J, Back JW, Falk CS, et al. The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy. Cellular & Molecular Immunology. 2019;16(10):791-9.DOI: https://doi.org/10.1111/j.1365-2249.2009.03979.x
25. Al-Rawi ZS, Alazzawi AJ, Alajili FM, Alwakil R. Rheumatoid arthritis in population samples in Iraq. Annals of the Rheumatic Diseases. 1978;37(1):73-5. DOI: http://arthritis-research.com/content/15/S1/S4